CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy

The development of chimeric antigen receptor T cells (CAR-T cells) has marked a new era in cancer immunotherapy. Based on a multitude of durable complete remissions in patients with hematological malignancies, FDA and EMA approval was issued to several CAR products targeting lymphoid leukemias and l...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrer, Dennis Christoph, Dörrie, Jan, Schaft, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916546/
https://www.ncbi.nlm.nih.gov/pubmed/36768665
http://dx.doi.org/10.3390/ijms24032342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916546/
https://www.ncbi.nlm.nih.gov/pubmed/36768665
http://dx.doi.org/10.3390/ijms24032342

Ejemplares similares